Indicateurs
1 Consultations de la notice
- Titre
- 219 Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities
- Créateurs - sans rôle
- Bernard Combe - Rhumatologie, CHRU Montpellier, Montpellier, FRANCEAlejandro Balsa - Hospital Universitario La PazKevin Winthrop - University of PortlandHans-Peter Tony - Rheumatology and Clinical Immunology, Dept. of Medicine 2, University of Wuerzburg, Wuerzburg, GERMANYMark C Genovese - Stanford UniversityMasayoshi Harigai - Department of Pharmacovigilance, Tokyo Women's Medical University, Tokyo, JAPANJosef S Smolen - Division of Rheumatology, Medical University of Vienna, Vienna, AUSTRIAPaul Emery - Leeds MSK Biomed, Chapel Allerton Hosp, Leeds, UNITED KINGDOMJean Dudler - Service de rhumatologie, Hôpital Cantonal, Fribourg, SWITZERLANDStephen Hall - Cabrini Medical Centre, Cabrini Private Hospital, Malvern, Victoria, AUSTRALIACristiano A Zerbini - CEPIC, Centro Paulista de Investigacao Clinica, Sao Paulo, BRAZILFilip Van Den Bosch - Ghent University HospitalFrederick Durand - Biomed, Lilly France, Neuilly-sur-Seine, FRANCESubhashini Arthanari - Eli Lilly UK, Eli Lilly and Company Ltd, Basingstoke, UNITED KINGDOMVeronica Rogai - Biomed, Eli Lilly Italia S.p.A., Sesto Fiorentino, ITALYJinglin Zhong - Statistics, Quintiles IMS, Morrisville, NY, USAGabriella Meszaros - Biomed, Eli Lilly Ges.m.b.H., Vienna, AUSTRIAMaxime Dougados - Department of Rheumatology, Cochin Hospital, Paris, FRANCE
- Détails de publication
- Rheumatology (Oxford, England), Vol.57(suppl_3)
- Identifiants
- 99233944809311
- Unité académique
- IGMM - Institut de Génétique Moléculaire de Montpellier
- Langue
- Anglais
- Type de ressource
- Article de revue scientifique